CA2717991A1 - Traitement pour des troubles oculaires - Google Patents

Traitement pour des troubles oculaires Download PDF

Info

Publication number
CA2717991A1
CA2717991A1 CA2717991A CA2717991A CA2717991A1 CA 2717991 A1 CA2717991 A1 CA 2717991A1 CA 2717991 A CA2717991 A CA 2717991A CA 2717991 A CA2717991 A CA 2717991A CA 2717991 A1 CA2717991 A1 CA 2717991A1
Authority
CA
Canada
Prior art keywords
compound
ocular
agents
patient
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2717991A
Other languages
English (en)
Inventor
Thomas Oligino
Chang Hahn
Timothy A. Gillespy
Ramalinga Dharanipragada
Ellen Matzkin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of CA2717991A1 publication Critical patent/CA2717991A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2717991A 2008-03-10 2009-03-05 Traitement pour des troubles oculaires Abandoned CA2717991A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3507308P 2008-03-10 2008-03-10
US61/035,073 2008-03-10
PCT/US2009/036119 WO2009114373A1 (fr) 2008-03-10 2009-03-05 Traitement pour des troubles oculaires

Publications (1)

Publication Number Publication Date
CA2717991A1 true CA2717991A1 (fr) 2009-09-17

Family

ID=40583469

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2717991A Abandoned CA2717991A1 (fr) 2008-03-10 2009-03-05 Traitement pour des troubles oculaires

Country Status (22)

Country Link
EP (1) EP2285378A1 (fr)
JP (1) JP2011513488A (fr)
KR (1) KR20110009084A (fr)
CN (1) CN101965188A (fr)
AR (1) AR070975A1 (fr)
AU (1) AU2009223501A1 (fr)
BR (1) BRPI0909659A2 (fr)
CA (1) CA2717991A1 (fr)
CL (1) CL2009000551A1 (fr)
CO (1) CO6290691A2 (fr)
CR (1) CR11644A (fr)
DO (1) DOP2010000266A (fr)
IL (1) IL207906A0 (fr)
MA (1) MA32211B1 (fr)
MX (1) MX2010008308A (fr)
NI (1) NI201000131A (fr)
NZ (1) NZ587906A (fr)
RU (1) RU2010141560A (fr)
SV (1) SV2010003658A (fr)
TW (1) TW200950784A (fr)
WO (1) WO2009114373A1 (fr)
ZA (1) ZA201005337B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR074776A1 (es) 2008-12-18 2011-02-09 Sanofi Aventis Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente
EP2441755A1 (fr) 2010-09-30 2012-04-18 Almirall, S.A. Dérivés de pyridine et isoquinoline comme inhibiteurs des kinases Syk et JAK
EP2489663A1 (fr) 2011-02-16 2012-08-22 Almirall, S.A. Composés en tant qu'inhibiteurs de la syk kinase

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1615873A (zh) * 1999-12-24 2005-05-18 阿文蒂斯药物有限公司 氮杂吲哚类化合物
CA2400923A1 (fr) * 2000-02-25 2001-08-30 Merck & Co., Inc. Inhibiteurs de tyrosine-kinase
NZ567241A (en) * 2005-09-30 2010-08-27 Miikana Therapeutics Inc Substituted pyrazole compounds
CL2007002617A1 (es) * 2006-09-11 2008-05-16 Sanofi Aventis Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.

Also Published As

Publication number Publication date
TW200950784A (en) 2009-12-16
MA32211B1 (fr) 2011-04-01
WO2009114373A1 (fr) 2009-09-17
DOP2010000266A (es) 2010-09-30
IL207906A0 (en) 2010-12-30
AU2009223501A1 (en) 2009-09-17
MX2010008308A (es) 2010-08-11
KR20110009084A (ko) 2011-01-27
RU2010141560A (ru) 2012-04-20
ZA201005337B (en) 2011-04-28
CO6290691A2 (es) 2011-06-20
NZ587906A (en) 2011-12-22
JP2011513488A (ja) 2011-04-28
CN101965188A (zh) 2011-02-02
SV2010003658A (es) 2011-01-31
CR11644A (es) 2010-11-22
NI201000131A (es) 2011-09-29
BRPI0909659A2 (pt) 2015-09-22
EP2285378A1 (fr) 2011-02-23
AR070975A1 (es) 2010-05-19
CL2009000551A1 (es) 2009-08-21

Similar Documents

Publication Publication Date Title
JP5875191B2 (ja) Cmt及び関連障害を処置するための新たな組成物
JP2019142917A (ja) Cmt及び関連疾患の処置のための新規な治療的アプローチ
JP5404045B2 (ja) 神経および非神経痛を治療する方法
KR101663998B1 (ko) 샤르코-마리-투스 질환 및 관련 장애를 치료하기 위한 필로카핀 및 메티마졸 조합
Zhang et al. Inflammatory mechanisms contribute to the neurological manifestations of tuberous sclerosis complex
JP6300856B2 (ja) ゼブラフィッシュモデルを用いることにより薬物をスクリーニングする方法、及びこの方法によりスクリーニングされた化合物
JP2004532809A (ja) ホスホジエステラーゼ4型を阻害することによって、神経系の再生および修復を刺激するための方法
JP2000514402A (ja) Vegfに関連する目の病気に関する治療処置
JP2021521263A (ja) 眼疾患を治療するための脱メチル化
US20100004244A1 (en) Use of cb2 receptor agonists for promoting neurogenesis
CA2717991A1 (fr) Traitement pour des troubles oculaires
US20110112101A1 (en) Treatment for ocular-related disorders
Sharif et al. Human trabecular meshwork cells express functional serotonin-2A (5HT2A) receptors: role in IOP reduction
US20210196716A1 (en) Compositions and methods for treating eye disorders
Megat et al. Antiallodynic action of phosphodiesterase inhibitors in a mouse model of peripheral nerve injury
US20120100229A1 (en) Treatment and Prevention of White Matter Injury with KATP Channel Activators
JP2020519581A (ja) 肥満細胞疾患の処置のための方法及び医薬組成物
US11730769B2 (en) Compositions and methods for Williams Syndrome (WS) therapy
WO2024089691A1 (fr) Modulateurs et leurs utilisations
WO2022217035A1 (fr) Activateurs de la voie de réponse au stress intégrée pour la protection contre la ferroptose
WO2024100421A1 (fr) Inhibiteurs de sarm1 utilisés en thérapie et en cosmétique
US20160038521A1 (en) Therapeutic methods

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20130305